Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125054) titled 'Study on the efficacy of Tildrakizumab in treating moderate to severe plaque psoriasis and its effects on tissue-resident T cells' on May 20.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Guangzhou Dermatology Hospital
Condition:
Moderate to severe plaque psoriasis
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-20
Target Sample Size: Experimental group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=319533
Published by HT Digital Content Services with permission from Health Daily Diges...